OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
OS Therapies (NYSE-A: OSTX) ('OS Therapies' or 'the Company'), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2. The movie will premiere on April 3, 2025 at AMC Century City in Los Angeles and will be available to stream through the PBS app and on PBS.org starting in May.
'Our team is dedicated to advancing a treatment for osteosarcoma and are proud to see our immunotherapy in Shelter Me: The Cancer Pioneers,' stated OS Therapies' CEO Paul Romness. 'Comparative oncology is an important area of research for us because of the striking genetic homology of over 96% between human and canine osteosarcoma.' OST-HER2 is an investigational drug and is not currently approved to treat osteosarcoma or any other disease.
Shelter Me: The Cancer Pioneers also features leading scientists at the National Cancer Institute / National Institutes of Health, the University of Pennsylvania, the University of Illinois, the University of Wisconsin, and Colorado State University. It is part of an Emmy Award-winning PBS series, Shelter Me, that celebrates the life-changing relationships between people and animals.
A trailer of the movie can be viewed here.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as 'anticipate,' 'expect,' 'intend,' 'may,' 'will,' 'should' or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in the Company's registration statement on Form S-1 filed with the Securities and Exchange Commission (the 'SEC') on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Jack Doll
571.243.9455
[email protected]://x.com/OSTherapies
https://www.instagram.com/ostherapies/
https://www.facebook.com/OSTherapies/
https://www.linkedin.com/company/os-therapies/
SOURCE: OS Therapies
Copyright Business Wire 2025.
PUB: 03/25/2025 07:40 AM/DISC: 03/25/2025 07:39 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
EBC Financial Group Launches Over a 100 U.S. ETF CFDs, Strengthening Diversification for Global Clients
LONDON--(BUSINESS WIRE)--EBC Financial Group (EBC) has announced the launch of over 100 new U.S.-listed Exchange-Traded Fund (ETF) CFDs, expanding its multi-asset product suite and offering global client's deeper access to diversified, thematic trading opportunities. The rollout highlights EBC's ongoing commitment to delivering institutional-grade tools across asset classes, underpinned by flexibility, transparency, and efficiency. The new offering includes ETFs listed on the NYSE and NASDAQ, issued by leading asset managers such as Vanguard, iShares (BlackRock), and State Street Global Advisors. Thematic coverage spans a wide range of global macro and sectoral narratives. 'This expansion reflects our vision to bridge intelligent product design with market relevance,' said David Barrett, CEO of EBC Financial Group (UK) Ltd. 'The new products are a natural evolution for traders seeking targeted exposure with greater strategic flexibility. At EBC, we're building an ecosystem that empowers both precision and performance.' Thematic Access Meets Tactical Flexibility The additional ETF-linked instruments cover a variety of market exposures, including geographic allocations like the iShares MSCI Brazil ETF; fixed income-focused strategies such as the iShares iBoxx $ High Yield Corporate Bond Fund; and sector- or commodity-based indices including the United States Oil Fund LP and the Vanguard Health Care ETF. Other themes include dividend-related baskets, mid-cap equities, and style-based index tracking. These developments reflect wider industry interest in instruments that mirror trends in asset allocation without direct ownership of the underlying securities. Across many markets, sector-tilted and style-based index products are gaining relevance as participants seek flexible ways to align with global narratives. Historically, ETFs tracking specific economic cycles—such as commodity recoveries or emerging market rebounds—have demonstrated performance differentiation. The iShares MSCI Brazil ETF, for example, notably outperformed the S&P 500 during the post-pandemic recovery period in 2021, highlighting how thematic instruments can diverge from broad indices depending on market cycles. These additions serve as both stand-alone trade ideas and complementary instruments alongside EBC's existing product lineup, enabling advanced portfolio structuring and thematic trading. Smarter Exposure: Leverage, Shorting, and Cost Efficiency in One Product Compared to direct ETF investments, it presents several key advantages as traders benefit from a simplified cost structure, with no traditional fund management fees or broker commissions. The flexibility to take both long and short positions allows for strategic trading regardless of market direction, while the use of leverage enhances capital efficiency and return potential. These trades are executed in real time via EBC's recognised platforms, providing seamless access to market opportunities. During key market cycles, for example the post-pandemic V-shaped recovery of 2021—certain thematic ETFs, like the iShares MSCI Brazil ETF, significantly outperformed broader indices such as the S&P 500. Our portfolio enables traders to participate in similar trends, adapting quickly to shifting market dynamics with precision and speed. Getting Started These products can be accessed by registering on to begin simulated or live trading. About EBC Financial Group Founded in London's esteemed financial district, EBC Financial Group (EBC) is a global brand known for its expertise in financial brokerage and asset management. Through its regulated entities operating across major financial jurisdictions—including the UK, Australia, the Cayman Islands, Mauritius, and others—EBC enables retail, professional, and institutional investors to access a wide range of global markets and trading opportunities, including currencies, commodities, shares, and indices. Recognised with multiple awards, EBC is committed to upholding ethical standards and is licensed and regulated within the respective jurisdictions. EBC Financial Group (UK) Limited is regulated by the UK's Financial Conduct Authority (FCA); EBC Financial Group (Cayman) Limited is regulated by the Cayman Islands Monetary Authority (CIMA); EBC Financial Group (Australia) Pty Ltd, and EBC Asset Management Pty Ltd are regulated by Australia's Securities and Investments Commission (ASIC); EBC Financial (MU) Ltd is authorised and regulated by the Financial Services Commission Mauritius (FSC). At the core of EBC are a team of industry veterans with over 40 years of experience in major financial institutions. Having navigated key economic cycles from the Plaza Accord and 2015 Swiss franc crisis to the market upheavals of the COVID-19 pandemic. We foster a culture where integrity, respect, and client asset security are paramount, ensuring that every investor relationship is handled with the utmost seriousness it deserves. As the Official Foreign Exchange Partner of FC Barcelona, EBC provides specialised services across Asia, LATAM, the Middle East, Africa, and Oceania. Through its partnership with United to Beat Malaria, the company contributes to global health initiatives. EBC also supports the 'What Economists Really Do' public engagement series by Oxford University's Department of Economics, helping to demystify economics and its application to major societal challenges, fostering greater public understanding and dialogue.
Yahoo
an hour ago
- Yahoo
Could Roblox Stock Help You Become a Millionaire?
Roblox has built a compelling ecosystem and revenue model around user-created games. The stock has risen more than 160% over the last year. Roblox's millionaire-maker status may come down to its valuation and market cap. 10 stocks we like better than Roblox › Roblox (NYSE: RBLX) has revolutionized video gaming in many respects. Its ecosystem supports user-created games and fosters social interaction to provide an enjoyable user experience. Taking that approach, it built an environment that draws an average of 98 million daily active users (DAUs) as of the first quarter of 2025. Such a value proposition drew investors to the stock during the pandemic's height. Even though the stock price dropped significantly in the 2022 bear market, its recovery has gained momentum over the last year. Amid its returns, investors may begin to wonder whether the stock price growth is such that it can turn small investors into millionaires. Let's take a closer look. Roblox offers a unique twist on video gaming. Namely, it is a gaming company that does not create games. The key to the company's success is its game creation platform, Roblox Studio. Through this, the product's users design the games and share them with the greater Roblox community. Thanks to its growing popularity, its 98 million DAUs increased by 26% over the last year alone. Historically, its following was particularly strong among users younger than the age of 13. That growth has accelerated with the over-13 crowd, and that user base now makes up 62% of total DAUs. Amid its growth, Roblox's business model gives it numerous revenue sources. Specifically, the company earns revenue when users purchase Robux, which is money within the Roblox ecosystem that gamers use to buy special abilities and avatar upgrades, along with clothing, accessories, or other virtual items within games. Outside of the games themselves, other revenue sources include premium subscriptions, digital ads, and fees from royalties that game developers earn from their games. Unfortunately, while the Roblox ecosystem and revenue model sound compelling, the state of Roblox's financials and stock may dash hopes of the stock making investors millionaires. For one, Roblox remains a money loser despite its business model. Indeed, in Q1, its revenue of more than $1 billion rose 29% year over year. However, because of non-cash charges, operating losses have persisted. Its $215 million net loss attributable to common shareholders in Q1 was a relatively modest improvement from the $271 million loss in the year-ago quarter. The company estimates revenue of $4.29 billion to $4.365 billion during 2025. That's a 20% annual increase, indicating that growth is likely to slow down. Additionally, the state of the stock may make it appear less like a millionaire-maker. It surged higher by more than 160% over the last year. Consequently, the market cap now stands at more than $64 billion, placing it firmly in large-cap territory. Despite those gains, the lack of profitability leaves it without a price-to-earnings (P/E) ratio, and the 16 price-to-sales (P/S) ratio is also its highest sales multiple since early 2022. That means investors are less likely to benefit from a rising valuation, diminishing the stock's potential as a multi-bagger. Ultimately, the state of Roblox's stock and its underlying financials make it unlikely to turn small investors into millionaires. Indeed, Roblox has built a compelling and fast-growing ecosystem. The number of users is likely to continue growing, which should lead to significant revenue growth for the foreseeable future. Unfortunately, profitability is likely years away. Additionally, the stock's past increases, valuation, and higher market cap indicate that Roblox has already achieved much of its potential growth. Although the entertainment stock should move higher over time, it will likely take a considerable investment to turn a shareholder into a millionaire at this stage of its development. Before you buy stock in Roblox, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Roblox wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Roblox. The Motley Fool has a disclosure policy. Could Roblox Stock Help You Become a Millionaire? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
MINISO Group Announces Results of Annual General Meeting
GUANGZHOU, China, June 12, 2025 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global value retailer offering a variety of trendy lifestyle products featuring IP design, today announced that all the proposed resolutions submitted for shareholder approval set out in the notice of its annual general meeting were duly adopted at the meeting held in Hong Kong today. About MINISO Group MINISO Group is a global value retailer offering a variety of trendy lifestyle products featuring IP design. The Company serves consumers primarily through its large network of MINISO stores, and promotes a relaxing, treasure-hunting and engaging shopping experience full of delightful surprises that appeals to all demographics. Aesthetically pleasing design, quality and affordability are at the core of every product in MINISO's wide product portfolio, and the Company continually and frequently rolls out products with these qualities. Since the opening of its first store in China in 2013, the Company has built its flagship brand "MINISO" as a globally recognized consuming brand and established a massive store network worldwide. For more information, please visit Investor Relations Contact: MINISO Group Holding LimitedEmail: ir@ +86 (20) 36228788 Ext.8039 View original content: SOURCE MINISO Group Holding Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
